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Abstract: In recent years, immunotherapy has become the most promising therapy for a variety of
cancer types. The development of immune checkpoint blockade (ICB) therapies, the adoptive transfer
of tumor-specific T cells (adoptive cell therapy (ACT)) or the generation of T cells engineered with
chimeric antigen receptors (CAR) have been successfully applied to elicit durable immunological
responses in cancer patients. However, not all the patients respond to these therapies, leaving a
consistent gap of therapeutic improvement that still needs to be filled. The innate immune components
of the tumor microenvironment play a pivotal role in the activation and modulation of the adaptive
immune response against the tumor. Indeed, several efforts are made to develop strategies aimed to
harness innate immune cells in the context of cancer immunotherapy. In this review, we describe
the contribution of innate immune cells in T-cell-based cancer immunotherapy and the therapeutic
approaches implemented to broaden the efficacy of these therapies in cancer patients.
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1. Introduction
Over the last decade, cancer immunotherapy, such as immune checkpoint blockade (ICB) and
adoptive cell therapy (ACT), has emerged as revolutionary advances in cancer treatment. The impact
of these new approaches led to the assignment of the Nobel Prize for Medicine to James Allison and
Tasuku Honjo in 2018 for their discoveries on negative immune regulation and the development of ICB.
Compared to conventional anticancer therapies that directly target the malignant cells, immunotherapy
exploits the patient’s own immune cells to recognize and eventually eliminate the tumor [1,2]. ICB elicits
activation of endogenous cancer-specific T cells by antibody-mediated blockade of the checkpoint
inhibitor molecules CTLA-4, programmed cell death protein-1 (PD-1) and programmed death-ligand-1
(PD-L1). CTLA-4 is expressed by activated T cells and regulatory T cells (Treg) [3] and induces immune
tolerance and T cell anergy upon binding to CD80 and CD86 expressed by antigen-presenting cells
(APC) [4]. Similarly, PD-1 is expressed by T cells and binds specific ligands called PD-L1 and PD-L2
presented by cancer cells and other immune components of the tumor microenvironment. PD-1
interaction with its ligands leads to T cell receptor (TCR) signaling inactivation and T cell exhaustion [4].
Since both CTLA-4 and PD-1 blocking antibodies target nonredundant pathways, they are currently
employed as monotherapy or in combination leading to encouraging and significant clinical benefits
in melanoma patients [5,6]. On the other hand, ACT consists of the transfer of a large number of
autologous antitumor T cells in lymphodepleted patients [7], where Tumor Infiltrated Lymphocytes
(TILs) are collected and expanded ex vivo before their reinfusion in the patient [8,9]. However, TILs
activity is often compromised due to the tolerogenic tumor microenvironment. Therefore, a new
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ACT protocol involving the isolation of autologous circulating T cells which are modified ex vivo
to acquire antitumoral activity have been developed [10]. In the last two decades, these therapies
have demonstrated durable clinical responses in patients affected by several cancer types [11–17].
Nevertheless, only 30% of the patients respond to these promising therapies, and to date, only a few
tumor types with high mutational load (melanoma, smoking-induced lung cancer and bladder cancer)
are suitable for immunotherapy [18]. The immune tolerance and T cell exclusion orchestrated by the
tumor microenvironment is thought to be the leading cause of immunotherapy failure with innate
immunity playing a central role.
Differently from adaptive immunity that recognizes specific nonself-antigen through a large repertoire
of rearranged receptors, innate immunity senses the tumor microenvironment and responds to a variety
of less-specific danger signals (pathogen-associated molecular patterns (PAMPs) and damage-associated
molecular patterns (DAMPS)) released from the affected cells [19]. The innate immune system can directly
inhibit tumor progression [20] by engaging tumoricidal activity. For example, natural killer cells (NKs)
are able to lyse tumor cells through the recognition of tumor-derived antigens or cell surface stress
molecules [21]. Moreover, polymorphonuclear granulocyte-like neutrophils and eosinophils mediate
antitumor activity through the antibody-dependent cellular cytotoxicity (ADCC) or antibody-dependent
cellular phagocytosis (ADCP) [22]. Similarly, macrophages can directly participate in tumoricidal activity
through ADCC and ADCP [23].
The innate immune cells participate also indirectly in antitumoral processes by recruiting adaptive
immune cells, mainly T cells, through the release of various inflammatory cytokines. T cell activation
is not an autonomous process and requires antigen presentation from specialized cells within a
proinflammatory environment. In this context, DCs and Macrophages are pivotal players contributing
to the tumor microenvironment inflammatory landscape. Importantly, T cell infiltration at the tumor
site has been proposed as a positive prognostic marker in immunotherapy [24]. T cell recruitment
in the tumor microenvironment is orchestrated by a large set of chemokines and cytokines [25]
especially produced by myeloid lineages component of the innate immunity such as DCs [26] and
macrophages [23]. Therefore, tackling the innate immunity has become an attractive therapeutic
opportunity to improve the efficacy of cancer immunotherapies [27].
Indeed, stimulation of innate immunity to treat cancer was first applied in the late 19th
Century [28,29]. Although without knowing the cellular mechanism involved, Coley achieved a
reduction in tumor growth, and, in certain cases, tumor elimination, by intratumoral injection of
inactivated bacteria (Streptococcus pyogenes and Serratia Marcenscens) [30]. Nowadays, we know that the
antitumor immune response in such contexts is triggered by the activation of innate immune response
via toll-like receptors (TLRs) recognitions of bacterial particles [31]. The role of innate immunity in
tumor development and progression has been deeply investigated for many years; however, over the
last decade, the cancer immunology field has centered its focus on the T cell antitumor capacity [27]. It is
undeniable that the application of T cell immunotherapy reached unprecedented therapeutic successes
in cancer treatment; however, its application is still limited to a few tumor types. In this context, innate
immunity is now drawing attention as a potential combinatory target for immunotherapy. Here, we
review the contribution of the most abundant myeloid components of the innate immune system on
the tumor immune landscape, their impact on the current T cell cancer immunotherapies and the
potential opportunities for the development of novel therapeutic strategies.
2. Dendritic Cells
Dendritic Cells (DCs) constitute a heterogeneous group of specialized APC, whose functions
are integrated into both the innate and the adaptive immune responses [32]. Their ability to capture,
process and present antigens are necessary for the initiation of antigen-specific immunity and, at the
same time, for the induction of immune tolerance [33,34]. In the absence of inflammatory stimuli,
DCs are defined as immature or tolerogenic. In this state, DCs express low levels of costimulatory
and immunoenhancing molecules such as CD40, CD80 and CD86 and contribute to the immune
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tolerance [35]. Immature DCs are known to infiltrate the tumor microenvironment [33,36] inducing
tolerance and anergy of tumor-specific T cells [37,38]. Furthermore, tolerogenic DCs along with
anti-inflammatory stimuli like TGF-β can increase immunosuppressive regulatory T cells (Treg)
population by conversion of naïve T cells or by the expansion of preformed Treg [39]. Conversely, in
the presence of inflammatory stimuli, bacterial or viral-derived products or by ligation with specific
receptors (e.g., CD40) DCs undergo maturation becoming a potent stimulator of adaptive immune
cells. Activated DCs express costimulatory molecules and chemokine receptors and are able to prime
T cells and trigger T cell killing activity against pathogens and cancer cells (Figure 1a). [40] Therefore,
DCs have the potential to generate and modulate the antitumor response by recruiting and activating
adaptive immunity [41]. Indeed, while dendritic cells are found to be a small cell population in both
lymphoid organs and tumor microenvironments, their manipulation hides a great potential for cancer
immunotherapy [34].
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Figure 1. Cross-talk between tumor microenvironment–innate immunity–T cell. (a) Dendritic cells
(DCs). DCs are recruit d in the tumor icroenvironment through a i s of cues released in the
tumor stroma. There, cancer cells produce a s ries of cytokines that pu s toward a tolerogenic
phenotype. On the other hand, when DCs are activated by DAMPs through their toll-like receptors
(TLRs), they mature and they sustain T cell activation and function. (b) Tumor-associated macrophages
(TAMs). TAMs generally display an M2 immunosuppressive phenotype. They are recruited by various
cytokines in the tumor microenvironment where they exploit their immunosuppressive function on T
cells through different mechanisms: release of tolerogenic cytokines and checkpoint molecules.
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Notably, conventional anticancer therapies influence immune cell recruitment and function and
their efficacy is often dependent on DCs activation. For example, chemotherapy, radiation and
cryoablation therapy can promote immunogenic cell death [42] and antitumor immunity by different
mechanisms orchestrated by DCs [43–45]. Dying cancer cells are characterized by the expression
of the “eat-me” signal calreticulin that is required for DC-mediated phagocytosis and consequent
induction of antitumor immunogenicity [46]. Furthermore, tumor cell death leads to the release
of immunostimulatory molecules such as ATP and Annexin A1 able to recruit DCs in the tumor
microenvironment [47,48]. Consequently, DCs accumulation enhances tumor-associated antigen
(TAA) cross-presentation and increases the recruitment of TAA-specific CD8+ cytotoxic T cells in the
tumor [49].
Besides conventional anticancer therapies, new strategies aimed to exploit DC functions are
currently pursued. Tumor vaccines, based on the administration of specific cytokines or/and adjuvants
promoting DC activation and thus T cell priming against tumor antigens, have shown promising
results in preclinical tumor models. Cytokines such as the FMS-like tyrosine kinase 3 ligand (FLT3L) or
the granulocyte–macrophage colony-stimulating factor (GM-CSF) are able to recruit and activate DCs
in the tumor microenvironment [50,51] and are currently being tested in different clinical trials as mono
or combinatorial therapy (Figures 1a and 2) [52]. Moreover, cancer cells can impair DC maturation by
the secretion of soluble molecules, such as Wnt1, or cytokines like IL-10, which activates pro-oncogenic
signaling pathways (e.g., STAT3). In this context, agents blocking Wnt1 or STAT3 signaling have shown
to relieve immunosuppression at the tumor sites and are currently evaluated in clinical trials for lung
adenocarcinoma and hematological malignancies [53–55].
Other strategies adopted in cancer therapy aim to block the DC immunosuppressive functions.
In the tumor microenvironment, DCs express the enzyme indoleamine 2,3-dioxygenase (IDO) which
depletes the amino-acid tryptophan, an essential nutrient required for proper T cell function (Figure 2).
Combinatorial targeting of IDO immunosuppressive role with ICB has been clinically tested and has
emerged as promising cancer therapy for a variety of cancer types (e.g., melanoma, ovary, breast,
myelodysplastic syndrome (MDS)) [56].
Moreover, DC proliferation and infiltration are promoted by immune checkpoint blockade (ICB)
therapy, unleashing antitumor adaptive immunity [57]. Interestingly, DCs express PD-L1 making them
a direct target of ICB. For example, it has been shown that PD-L1 blockade in DCs improves T cells
priming and overall survival of lung and renal carcinoma patients [58].
Conversely, tumors poorly infiltrated by DCs result resistant to ICB therapy [59]. The transfer of
in vitro preactivated DCs improves ICB efficacy in nonresponsive preclinical models of melanoma [60].
This evidence has led to the development of novel strategies aimed to improve ICB through the
chemokine-driven recruitment of endogenous DCs in the tumor microenvironment. The administration
of an engineered fusion form of the chemokine CCL4 targeting the tumor stroma enhances both DCs
and T cell immune infiltration and markedly boosts the responsiveness to ICB in poorly T-cell-infiltrated
tumors (cold tumor) [61]. Indeed, CCL4 is an important chemokine involved in the recruitment of DCs
in the tumor microenvironment through its receptor CCR5 and the lack of CCL4 has been described as a
hallmark of cold melanoma tumor [62]. In lung carcinoma patients the expression of a mutated variant
of EGFR in the tumor stroma leads to a drastic reduction of intratumoral DCs and consequent reduction
of T cells infiltration. Treatment with GM-CSF in combination with the EGFR receptor inhibitor gefitinib
rescued the DC population and ameliorated the response to ICB therapy [63–65]. Moreover, activation
of DCs via administration of toll-like receptors (TLRs) agonists has led to encouraging results when
combined with ICB. TLRs are expressed in DCs and other innate immune cells such as macrophages.
TLRs recognize pathogen-associated molecular patterns derived from microbes, damaged or necrotic
cells, and trigger both innate host defense responses (phagocytosis, inflammation) and antigen-specific
adaptive immunity [66] (Kawasaki and Kawai, 2014). Congruently, melanoma patients showed a better
clinical response and DCs infiltration when ICB was combined with TLR9 agonist treatment [67].
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Figure 2. Direct and indirect contribution of innate immune cells in T-cell-based immunotherapy.
Innate immune cells can modulate T-cell-based immunotherapy (immune checkpoint blockade (ICB)
and adoptive cell therapy (ACT)) through different mechanisms. Depending on the maturation status
DCs can boost or inhibit antitumor T-cell-based functions. Several approaches are aimed to promote DC
maturation or to inhibit DC tolerogenic activity. Notably, macrophages show, as DCs, a dichotomous
behavior in modulating immunotherapy efficacy. Their role is depending on their phenotype, M1 or
M2, and several therapies point to skew the differentiation process towards the more antitumoral M1
phenotype. On the other hand, myeloid-derived suppressor cells (MDSCs) participate in mounting
immunosuppression in the tumor microenvironment by releasing different cytokines and metabolites
that inhibit T cell function. Furthermore, granulocytes, like eosinophils and neutrophils, participate in
tuning the T cell activity in combination with classical immunotherapies. Some examples of activator or
inhibitory molecules produced by innate immune cells are shown. Red dotted arrows indicate relevant
therapeutically targeted molecules aiming to boost T-cell-based immunotherapies.
However, the application of DC-based strategies in cancer immunotherapy is not only restricted in
the context of ICB but has been successfully applied in T-cell-based cancer therapy [68]. Tumor-resident
DCs are required for proper tr fficking of adoptiv ly transferred T cells (ACT) and their scarcity
in the tu or stroma limits the therapeutic efficacy of transferred tumor-specific T cells in different
preclinical models [69]. Accordingly, the paucity of DCs in the stroma of pancreatic tumors has
been associated with their unresponsiveness to immunotherapy. DC mobilization and activation via
FLT3 administration elicit CD8 T cell priming and an effective antitumor response in an inducible
experimental model of pancreatic cancer [70]. CD8 T cell priming and activation require the interaction
with mature and activated DCs to mediate antitumoral and antipathogens activities. facilitating CD8 T
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cell–DC interactions via overexpression of the C-C chemokine receptor type 4 (CCR4) in CD8 T cells,
enhance T cell antitumor responses against pancreatic tumor models [71,72].
As described above, DCs actively participate in the priming and activation of adaptive immunity
through direct cell–cell interaction. However, the DC’s role is not limited or restricted at the first steps
of T cell activation process, but continues with significant contribution during T cell response with
the release of cytokines (e.g., tumor necrosis factors, TNFs) and metabolites sustaining T cell function
(Figures 1a and 2) [73].
Importantly, tumor immunotherapy aims not only to kill cancer cells, but also to mount a long-term
protective immunity mediated by memory CD8 T cells. In this context, DCs also play a central role in
the reactivation of tumor-specific memory T cells, ensuring not only short-term antitumor response
but also long-term antitumor immunization [74,75]. All this evidence places DCs as a central hub of
the antitumor immune response, being capable to orchestrate the complex multifaceted function of
adaptive immunity and making them an attractive target for future combinatorial therapies aimed to
enhance the efficacy of current T-cell-based immunotherapy.
3. Macrophages
Macrophages are multifunctional components of the innate immunity and consist of different
subgroups with different maturation stages and tissue localization [40]. They are the primary
defense against pathogens where they exploit their function through phagocytosis and the production
of inflammatory cytokines [76]. Indeed, in infection context macrophages are polarized toward
M1-phenotype through toll-like receptors (TLRs) and Th1 cytokines (e.g., interferon-γ; IFN-γ)
stimulation. M1 macrophages produce proinflammatory cytokines such as IL-12, IL-23 and TNFα
and increase their antigen-presenting capacity by boosting the expression of major histocompatibility
complex class II (MHC-II) and costimulatory molecules [77]. Conversely, Th2 cytokines, such as IL-4
and IL-13, polarize the macrophages toward M2-phenotype. M2 macrophages have a pronounced
anti-inflammatory function through the production of IL-10 and immunosuppressive metabolites of
adaptive immunity and they are strongly involved in tissue remodeling and angiogenesis [77,78].
These two subgroups of macrophages participate during two distinct phases of a pathogen infection:
the acute phase, where M1 macrophages play a key role in mounting the immune response, and
the resolution phase, where M2 macrophages participate in dumping the immune response and
tissue repair.
Tumor-associated macrophages (TAMs) are an important component of the immune landscape of
tumor microenvironment and normally present M2 polarization. They are recruited into the tumor
microenvironment by different chemokines such as CSF-1, G-CSF, CXCL12/SDF-1 and CCL2/MCP1
secreted by stromal and tumor cells [79]. These recruitment factors are specially produced within the
hypoxic regions of the tumor (core) that in turns lead to the preferential localization of macrophages in
the hypoxic microenvironment [80]. In hypoxic conditions, the activation of hypoxia-inducible factors
(HIFs) in macrophages resulted in the selective promotion of the M2 immunosuppressive phenotype
with consequent inhibition of T cell-mediated adaptive immunity [81]. Moreover, TAMs help tumor
establishment by secreting factors that promote proliferation, angiogenesis, dissemination and distant
site colonization [76] and their abundance in the tumor stroma correlates with a poor prognosis of the
disease progression [82].
TAM can directly hamper T cell adaptive immunity. Indeed, high expression of arginase-1 (Arg-1)
in M2 macrophages leads to the depletion of L-arginine in the tumor microenvironment that is required
for T cell fitness and antitumor activity [83,84]. Congruently, mice engrafted with a murine cell
line of lung carcinoma have enhanced response to immunotherapy when treated with an arginase
inhibitor [85]. Nitric oxide synthase 2 (NOS2) is highly expressed in M2 macrophages and participates
in the degradation of L-arginine and the generation of nitric oxide (NO) [86]. Moreover, NO has
a direct effect on T cell activation and the use of NO-scavenger has been shown to enhance T cell
response to tumor vaccination (Figure 1b) [87]. However, recent studies suggest that the effect of
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NOS2 in the tumor microenvironment is context-dependent and, in certain cases, can enhance T cell
antitumor response [73,88] via induction of vascular cell adhesion molecule 1 (VCAM1) in the tumor
endothelium and consequently increased accumulation of adoptively transferred CD8+ T cells [88].
Importantly, CD14+ or CD68+ macrophages express immune checkpoint ligands that can directly
interact with T cells and hamper their antitumor activity [84]. Congruently, TAMs isolated from
hepatocellular carcinoma (HCC) patients showed enhanced expression of PD-L1, which correlated with
patient disease progression and mortality [89]. Moreover, recent studies have demonstrated that the
efficiency of anti-CTLA-4 checkpoint therapy in prostate cancer patients was hampered by the presence
of CD68+ macrophages expressing PD-L1 or V-domain Ig suppressor of T cell activation (VISTA).
Together with changes in the macrophage population, patient nonresponders to anti-CTLA-4 therapy
showed a higher proportion of CD4+, CD8+ T cells [90]. Notably, CD68+ macrophages expressing
PD-L1 or VISTA displayed an M2 polarization characterized by increased expression of CD163 and
Arg1. Another immune checkpoint ligand, B7-H4, is highly expressed in TAMs and strongly inhibits
IL-2 production and T cell proliferation [91]. Indeed, TAMs present in various human tumor types
display high expression of PD-L1 and/or B7-H4 (Figure 1b). However, the contribution of these TAM
checkpoint ligands to the overall immunosuppression occurring in the tumor microenvironment
still needs to be fully elucidated [23]. In this context, ICB is often not sufficient to overcome the
macrophage-induced T cell immunosuppression [92]. An increased body of evidence indicates that
TAMs can directly suppress T cell tumor infiltration [84] and thus strongly hinder the efficacy of
cancer immunotherapy [93,94]. ICB effectiveness has been successfully achieved when combined with
inhibitors of macrophages recruitment in the tumor microenvironment. Therapies combining CCR2 or
CSFR-1 antagonists with anticheckpoint antibodies have shown promising results in various cancer
models refractory to standard ICB (Figure 2) [84,92]. In these systems, TAM depletion leads to an
increased T cell tumor infiltration and thus to an enhanced response to immunotherapy [95] for which
several cellular and molecular mechanisms have been proposed [84]. One interesting mechanism
that could be involved in the T cell immune exclusion arises from recent studies showing that TGFβ,
abundantly produced by TAM, restrains T cell infiltration in both colorectal cancer mouse models and
metastatic urothelial cancer patients [96,97].
Finally, TAMs can suppress adaptive immunity through the recruitment of immunomodulatory
cell populations in the tumor microenvironment such as myeloid-derived suppressor cells (MDSCs)
and regulatory T cells [98–100].
The importance of macrophages in modulating antitumor immune response has led to the
development of several strategies aimed to enhance the efficacy of T cell immunotherapy. In both
preclinical and clinical settings, better efficacy has been observed when classical immunotherapies were
combined with macrophage-targeting strategies. This evidence indicates that the major contribution of
macrophages in tumor immunosuppression is exerted through the inhibition of adaptive immunity.
Some of the approaches nowadays tested in clinical trials are aimed to reprogram macrophages
toward M1 polarization and thus toward a more proinflammatory phenotype. Targeting the TNF
superfamily member CD40, expressed both by macrophages and DCs, with agonist antibodies have
been successfully used to increase antigen-presenting capacities of APCs and elicit tumor-specific T
cell priming and activation [101]. Even though the therapeutic contribution, in certain cases, seems
to be attributable to DCs [73] and in other to macrophages [102], this approach is currently tested in
different clinical trials in combination with checkpoint blockade immunotherapy in metastatic lung
and melanoma patients. An alternative strategy to reprogram macrophages involves the targeting
of their metabolism through the inhibition of PI3Kγ signaling, which has been shown to be an
important molecular hub orchestrating macrophages immunosuppressive activity (Figure 2) [103].
Indeed, inhibition of PI3Kγ results in macrophage reprogramming and increased T cell response [84].
This therapeutic approach is currently tested in clinical trials in combination with checkpoint blockade
immunotherapy in refractory Hodgkin lymphoma patients.
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However, the most explored strategies at the moment are targeting macrophage recruitment and
survival. As mentioned previously, antibodies against CCL2/CCR2 and CCL5 have been employed
in preclinical models in combination with checkpoint blockade immunotherapy with encouraging
results in several tumor types [100,104,105]. Indeed, CCR2 antagonists are currently tested in
patients with advanced melanoma in combination with anti-PD1 or PDL1 therapy. Other pathways
regulating macrophage recruitment involved the CXCL12/CXCR4 and angiopoietin2 (ANG2)/TIE2
axes. These therapies especially affect TIE2+ TAMs that have been shown to be involved in tumor
angiogenesis and malignant progression [106]. ANG2 targeting is currently tested in combination with
anti-PD1 therapy in advanced melanoma, ovarian, renal or colorectal carcinomas [84]. TAM abundance
is also modulated with novel therapies acting on cell survival. Antagonists acting on CSF/CSFR1
strongly induce apoptosis in TAMs and influence T cell infiltration and response to both ICB and
ACT (Figure 2) [84]. Several clinical trials are currently conducted in patients with advanced solid
tumors and promising results have been achieved in the treatment of nonresponsive pancreatic cancer
patients [84].
Globally, these data indicate that modulation of macrophage recruitment, survival and function
can represent a valuable target to improve T cell immunotherapy and further combinatorial approaches
possibly will lead to an overall improvement of immunotherapy.
4. Myeloid-Derived Suppressor Cells (MDSC)
Myeloid-derived suppressor cells (MDSC) are defined for their ability to suppress T-cell-mediated
immune responses, to support tumor progression and to promote a more invasive and malignant
phenotype [107]. They represent a heterogeneous immune cell population originally defined by
the expression of CD11b and Gr1 markers. However, additional markers associated with their
immunosuppressive functions have been identified, such as CD80, CD115 (CSF-1 or M-CSF-receptor),
CD124 (IL-4 receptor alpha chain) [107].
MDSCs are composed of two morphologically defined subpopulations: monocytic MDSC
(M-MDSC), expressing CD11b+ Gr1+ Ly6G- Ly6Chigh markers, and polymorphonuclear (PMN-MDSC),
expressing granulocytic/neutrophil-like markers such as CD11b+ Gr1+ Ly6G+ Ly6Clow [108]. MDSCs
are mobilized from the bone marrow and recruited into the primary tumor site through various
chemo-attractant factors such as M-CSF, GM-CSF, CCL-2 (MCP-1), CCL-5 (RANTES), Bv8 [109,110],
which are particularly secreted in hypoxic regions of the tumor (Figure 2) [111].
Functionally, they have been characterized for their capacity to suppress T cell-mediated immune
responses. Different immunosuppressive mechanisms have been described, including the release
of tolerogenic cytokines and nitric oxide (NO), the generation of reactive oxygen species (ROS),
and induction of L-Arginase. As a result of the activity of these enzymes (iNOS and Arg2), the tumor
microenvironment is depleted of L-arginine, impeding T cell proliferation, activation and antigen
recognition, and finally favoring a tolerogenic tumor milieu (Figure 2) [112].
MDSCs can directly hamper adaptive immunity through the release of type 2 cytokines, such as
IL-10 and TGF-β, or indirectly by promoting M2 polarization of macrophages, hindering the release of
type 1 cytokines, such as IL-12.
More recently, MDSCs have been studied for their influence on anticancer immunotherapies.
The presence of MDSCs in both tumor infiltrate and blood circulation correlates to reduced
overall survival (OS) and to worse outcomes in breast, lung and colorectal cancer patients.
These immunosuppressive cells are preferentially recruited in advanced tumor stage and size, leading
to a negative contribution in melanoma patient response to immunotherapy [113,114]. To improve
immunotherapy efficacy and counteract MDSC tumor-promoting and immunosuppressive functions,
in the last years, novel therapeutic strategies have been developed acting at different levels of MDSC
contribution. For example, it has been shown that all-trans retinoic acid (AT-RA) is able to reduce
the MDSC number in circulation (expansion) [115]. Moreover, the blockade of VEGF-receptor, c-Kit
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signaling, or upon cytotoxic agent treatments, as gemcitabine and 5-fluorouracil (5FU), specifically
induce apoptosis in MDSCs (Figure 2) [116,117].
Other strategies involve the inhibition of their recruitment in the tumor microenvironment, such
as interventions targeting the CCL2 axis by CCR5 receptor antagonists. Indeed, in a mouse model
of neuroblastoma the blockade of CSF-1 (M-CSF)/CSF-1R signaling inhibited MDSC recruitment
and improved the response to anti-PD-1 therapy [118]. On the other hand, targeting the MDSC
interference on T-cell-mediated immune response via the inhibition of phosphodiesterase showed to
act synergistically with PD-1 blockade in preclinical models as in ongoing clinical trials, similarly to
the HDAC inhibitor entinostat [119,120],.
Another interesting aspect that has been recently explored is the use of MDSCs as predictive
markers for response to ICB in metastatic melanoma patients, where patient responders to ipilimumab
showed a significantly lower fraction of circulating MDSCs as compared to the nonresponders [121].
Furthermore, preclinical studies have shown that the combination of MDSC depletion strategies
with ICB boosts the infiltration of adaptive immune cells, reduces metastatic progression and
increases survival rate in preclinical models of breast, lung and renal cell carcinoma [119]. Similarly,
the elimination of PMN-MDSC CXCR2+ trafficking with the small-molecule inhibitor SX-682 of
CXCR1/CXCR2 receptors resulted in an improved response to ACT in a syngeneic model of squamous
cell carcinoma (SCC) [122].
Globally, targeting MDSCs’ contribution to tumor progression could help to reshape the tolerogenic
tumor microenvironment and could improve T-cell-based cancer immunotherapies. However, MDSCs
share several targets with other myeloid components of the tumor microenvironment and the response
to a specific therapy still needs to be clearly attributed to the heterotypic cellular component of the
tumor stroma.
5. Neutrophils and Eosinophils
Neutrophils are the most abundant population of white blood cells in humans, playing important
roles in the inflammatory process and primary immune response [123]. They have been mainly
described as short-living immune cells and for their role in the clearance of extracellular pathogens.
However, this concept has been overstepped with the discoveries of their capacity to live much longer
than expected and to produce several key cytokines, chemokines and Fc receptors [124]. Nowadays,
evidence has demonstrated important contributions of neutrophils both in the promotion and inhibition
of tumor development and growth [125]. This dichotomy suggests that neutrophils are composed
of diverse cellular subsets. However, the identification of these subgroups has been trivial due to
the lack of robust surface cell markers [125], limiting their characterization of physical properties
and functionality [126]. Neutrophils are thought to support tumor growth and progression. Higher
neutrophils to lymphocytes ratio represent a poor prognostic marker for a variety of cancer types such as
lung and breast cancer [126]. Indeed, neutrophils can support metastatic colonization in a mouse model
of breast cancer, orchestrating the formation of the premetastatic niche in the lung [127]. Neutrophils
are recruited in the tumor microenvironment by a series of attracting CXC cytokines released by cancer
cells [124]. Furthermore, neutrophils are able to sustain tumor progression through the release of
proangiogenic factors such as VEGF and MMP9 [128,129] and, by maintaining an immunosuppressive
tumor microenvironment through the expression of the arginine-consuming enzyme Arg1 and ROS
production [130]. Arginine depletion and ROS directly inhibit T cell antitumor activity and, therefore,
neutrophils can negatively impact the efficacy of T-cell-based cancer immunotherapy (Figure 2).
As mentioned above, neutrophils can also exert cytotoxic activity against tumor cells. During
the first phases of tumor formation when the immunosuppressive environment is not yet completely
established [125] neutrophils recognize and kill cancer cells through ADCC. Neutrophils contribute to
tumor control and tumor eradication also by regulating the activation and function of adaptive immune
cells like CD4 or CD8 T cells [124,131]. Indeed, neutrophils also function as APC and thus can directly
interact with T cells, supporting a robust antitumor T cell activity. [132–136]. Conversely, neutrophils
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can recruit and activate Treg cells following the secretion of cytokines like CCL17 and promoting
an immunosuppressive environment (Figure 2) [137]. However, in the tumor microenvironment
neutrophils, as well macrophages, exert generally a tolerogenic activity and consequently hampering
the effectiveness of T-cell-based immunotherapy. In this context, TGFβ can polarize neutrophils toward
an immunosuppressive phenotype and hinder CD8 T cell tumor infiltration [133]. Blocking TGFβ in
the tumor boosts CD8 T cell infiltration and CD8 T cell-dependent antitumoral response [133]. On the
contrary, IFNβ has been shown to promote neutrophil antitumor activity and recruitment in the tumor
microenvironment [125,138].
Blocking the immunosuppressive function of tumor-infiltrating neutrophils has shown to improve
the effectiveness of T-cell-based immunotherapies, such as ICB and ACT. In a murine model of
melanoma, the inhibition of the receptor tyrosine kinase c-MET (HGF-R, hepatocyte growth factor
receptor) reduces neutrophil recruitment in the tumor microenvironment and in the draining lymph
nodes in response to immunotherapy (Figure 2). Consequently, c-MET inhibition enhances the response
to ICB and ACT [139]. Meanwhile, the inhibition of the fatty acid transporter protein 2 (FATP2) abrogate
neutrophil immunosuppressive activity and response to ICB [140]. In addition, under certain stress
conditions, neutrophils can release DNA-based structures, named neutrophil extracellular traps (NETs),
which enable neutrophils to capture and kill extracellular pathogens [141]. This cell death phenomenon
is nowadays called NETosis [142] and it represents a mechanism adopted by neutrophils to modulate
adoptive T cell immunity. NETs are able to interact with DCs enhancing their maturation [143,144],
resulting in the upregulation of costimulatory molecules such as CD40, CD80/CD86 and MHCII and
proliferation of CD4 T cells [145]. Furthermore, NETs can directly prime T cells leading to increased
expression of activation markers such as CD69 and CD25 [146]. Notably, T cells primed by NETs
were able to respond to specific antigens even in the absence of costimulatory signals. It is worth
noting that this scenario is common in the tumor microenvironment, and, therefore, NETosis can be
exploited to induce or to modulate the activation of tumor-specific T cells. However, neutrophilia and
NETs formation support disease progression and metastasis formation in lung and colon cancer, and
blocking NETosis resulted in decreased cancer cell dissemination [147]).
Furthermore, it has been shown that NETs can protect cancer cells against T cells and NK
cell-mediated cytotoxicity [148]. Tumors cells are able to recruit neutrophils and to sustain NETosis
through the secretion of neutrophils chemoattractants, like ligands of the chemokine receptors CXCR1
and CXCR2 [149]. NETs coated tumor cells were physically protected against adaptive immune
cells, impairing T cells and NK cells motility and blocking them from reaching the tumor. Notably,
pharmacological inhibition of NETosis sensitizes tumors to ICB therapy [149].
This evidence highlights the potential therapeutic opportunities in targeting neutrophils combined
with immunotherapies. However, neutrophil contribution to tumor development and progression still
needs to be fully elucidated [124] and neutrophil-targeting therapies capable of boosting T-cell-based
immunotherapy have not yet reached clinical applications.
Eosinophils participate in tissue repair processes and in the immune response against parasites.
Moreover, eosinophils play a role in several diseases like allergic asthma, autoimmune disorders
and cancer [150,151]. Although eosinophils were described in tumor samples at the end of the 19th
century and are known to infiltrate several tumor types [152], their function in tumor progression
and in the tumor microenvironment is still subject of investigation [153]. Studies have shown
increased eosinophil count upon ICB therapy in melanoma, prostate and lung cancer patients which
positively correlated with the disease prognosis [154–157]. The release of DAMPS by necrotic cells
in the tumor stroma is proposed to be responsible for eosinophil recruitment (eosinophilia) [158].
Indeed, eosinophil infiltration in the tumor microenvironment of melanoma patients treated with
ICB positively correlates with increased TILs infiltration and better patient outcome [159]. Activated
eosinophils are able to remodel and normalize tumor vasculature, promoting T cell infiltration and
boosting ACT efficacy [160]. In addition, eosinophils can support antitumor immunity modulating
macrophage polarization. Notably, proinflammatory cytokines such as INFγ and TNFα are produced
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by activated eosinophils. Therefore, when transferred together with T cells, activated eosinophils
promote the polarization of TAM toward the M1-like phenotype, contributing to the establishment of a
proinflammatory tumor microenvironment [160]. Due to their tumor-homing properties, eosinophils
are becoming novel potential targets to improve T-cell-based immunotherapies. In the preclinical
mouse model of hepatic, prostate and breast cancer, inhibition of the dipeptidyl-peptidase 4 (DPP4)
with the FDA approved drug sitagliptin enhances host eosinophil-mediated antitumoral activity and
contribute to ICB efficacy [161].
These promising studies can pave the way for new therapeutic strategies aimed to enhance
T-cell-based immunotherapy through DPP4 inhibition (Figure 2) [162].
6. Contribution of Aging on Innate Immunity and T-Cell-Based Immunotherapy
An important aspect that has been poorly explored but that bridges immunotherapy response
to the balance between lymphoid and myeloid compartments, is age. To some extent, cancer can be
considered as an age-related disease [163]. Notably, cancer primarily occurs in the elderly and for most
types of this disease, incidence rates progressively increase with age (0–24 years old, 1%; 25–49 years old,
10%; 50–74 years old, 53%; 75+ years old, 36%; Cancer Research UK) [164]. In this context, aging is
taking part to the erosion of immune competence, a process called immunosenescence, that manifests
robustly in the component of the adaptive immunity [165], as result of thymic atrophy [166], a decrease
of naïve T cell [167], reduction of memory function [168] and decrease of TCR repertoire [169]. Moreover,
aging strongly affects hematopoietic stem cell (HSC) potential [170] and skews them toward myeloid
lineages [171]. This process called myeloid bias dramatically reduces the efficiency of T cell production
and thus compromises immune reconstitution and immunosurveillance [172]. Similarly to aging,
chemotherapy produces substantial damages to the immune system by affecting HSC function, leading
to myeloid bias differentiation and subsequent immunosuppression [173]. Therefore, aged patients
or patients that have undergone several rounds of chemotherapy may have a reduced response to
immunotherapy. Indeed, in lung cancer, prior chemotherapy exposure was associated with reduced
benefit from PD-L1 blockade therapy, which was higher in chemotherapy-naïve patients [174].
Moreover, aging leads to a gradual decline of the capacity of our adaptive immune system to
recognize and eliminate the fret and it predisposes patients to a higher risk of infection and tumor
incidence. These observations raise the need to change the focus of immunotherapies from a T cell
centric to a broader view including the innate immune compartments. Notably, the expansion of the
innate immune compartment during aging or chemotherapeutic treatment plays an important role in the
success of T-cell-based immunotherapy. One important example is the expansion in aged individuals
of the heterogeneous population of immature MDSCs [175]. This myeloid population conferees
tumor tolerance and is generally expanded in cancer and inflammatory states [176]. Congruently, old
mice have a higher proportion of M2 macrophages both in the spleen and in the bone marrow [177],
while neutrophils in aged patients produce more anti-inflammatory cytokines [178]. Taken together,
all these phenomena contribute to the general inhibition of adaptive immunity response. In this
context, another possible strategy to tackle innate immunity-induced immunosuppression in aged or
chemotherapy-treated patients is to manipulate HSC fate toward lymphoid lineage [179], reducing
the myeloid compartments and, at the same time, preserving the lymphoid compartments. Some
approaches targeting HSCs metabolism, like NAD boosting strategies, have been shown to be able to
reprogram HSC fate toward lymphoid lineages [180,181] but their application in immuno-oncology
still needs to be further investigated. Recently it has been reported that prolonged fasting protects
against chemotherapy/aging-induced changes in HSC function in mice, by reducing circulating IGF-1
levels and as a consequence, inhibiting PKA activity [179]. Prolonged fasting, as well NAD boosters
supplementation, represents a potentially powerful means to protect against ravages of chemotherapy
and aging [179,182–184], perhaps allowing higher doses of the drugs or a more efficient application
of T-cell-based immunotherapy by preserving the correct balance between lymphoid and myeloid
compartments [182].
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7. Conclusions
The clinical successes of immuno-oncology arise primarily from a T cell-centered vision, which
relies on the capacity of infiltrated T cells in controlling and killing tumor cells. However, T cell
activation is not a cell-autonomous process and requires the contribution of several cell types of the
innate immunity orchestrating complex interactions within the tumor microenvironment. Innate
immunity plays a central role in cancer development and progression, both through the remodeling of
the tumor microenvironment and establishment of an immunosuppressive environment. The innate
immune cell capacity to modulate the adaptive immune response has inspired attempts and trials
aimed at hijacking these processes and unleashing a T cell antitumoral response. In the last years,
the importance of targeting innate immune cells is recognized by the increasing number of clinical
trials for both cancer or autoimmune disorders aimed to harness innate immunity [40]. An interesting
approach that has been recently developed contemplates the application of CAR technology to “non-T
cell” immune cells such as NK cells and macrophages [185,186]. Interestingly, macrophages have
better capacity to penetrate the tumor than T cells. Moreover, the engineered CAR macrophages have
direct phagocytic capability against the tumor and display M1 polarization and thus favoring the
recruitment and activation of adaptive immunity [186]. All these evidences highlight the necessity
to develop holistic approaches capable of dissecting the contribution and interplay of the different
immune components of the tumor microenvironment. T-cell-based approaches have been extremely
successful for the treatment of a variety of cancer types, but still not applicable to the majority of them.
Future directions of combinatorial therapies include the use of metabolic modulators that can
act both on the innate and adaptive immunity compartments [187,188] and, as in the case of NAD
boosters, protect against the ravages of aging [189]. In fact, NAD metabolism has been shown to play
an important role in macrophage effector function [187] and in supporting their proinflammatory
phenotype [190] and, at the same time, modulating antitumor T cell response [188] and protect against
T cell immunosenescence [189]. However, these studies still need further investigation in order to
better understand the global effect of metabolic modulators on the different components of the tumor
microenvironment and exclude possible support to growth or survival of cancer cells, as reported for
NAD metabolism in certain hematological malignancies [191–194].
Thus, further understanding of the contribution of the innate immune compartments to anticancer
adaptive immune response will be a key aspect to explore in order to develop combinatorial therapeutic
strategies that would expand the clinical response to cancer immunotherapy.
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